Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.
The partners aim to progress DRIVE’s EIDD-2801 into human clinical trials. EIDD-2801 is an orally bioavailable version of a ribonucleoside analogue that blocks the replication of various RNA viruses such as SARS-CoV2.
Under the alliance, Ridgeback obtained an exclusive licence for EIDD-2801 and will advance the candidate through clinical development to make it available for the ongoing pandemic.